Eukarÿs is deep-tech Biotech Company of the Genopole of Evry (France). We have developped a proprietary core technology with two main applications, which explains our mixed business model.
One a one hand we develop a radically innovative non-viral therapeutic approach named synthetic gene therapy, which can be used to treat most human diseases while initially focusing on the treatment of liver diseases and cancers. Synthetic gene therapy is designed as safe, non-integrative, well tolerated, self-vectorized, produced at an acceptable cost. Proof of concept of efficacy and tolerability has been obtained for our first therapy.
On the other hand, Eukarÿs also develops high performance bioproduction systems for biologics, including recombinant proteins, viruses and vaccines, and this activity should lead to the creation of an independent subsidiary maturing in 2024.
Finally, our goal is to demonstrate the effectiveness of the synthetic gene therapy in clinical studies, then to conclude a co-development agreement with Pharma in 2024. To achieve this goal and the next critical steps, our financing needs are estimated at between €18M, with current fundraising round of €300,000.
Publié le vendredi 6 décembre 2019 10:24
Eukarÿs is nominated among 9 other European companies at the EIT Health Summit 2019 at the Investor Network Start-Ups. The 2019 EIT Health Summit will be held at the Palais Brongniart in Paris on 2 and 3 December 2019.
Publié le vendredi 6 décembre 2019 10:22
Eukarÿs today announces the excellent preclinical performance of its first synthetic gene therapy treatment. This treatment called EUK-LPR ("Eukarÿs Liver ProRegeneration") is designed to reduce mortality and morbidity following partial hepatic resection by inducing liver regeneration prior to this surgical procedure. For specifically tumor indications of hepatectomy, including liver metastases of colorectal cancer, EUK-LPR will be associated with another synthetic gene therapy treatment whose development will be announced in 2020.
The tests performed in rats confirmed the excellent performance of EUK-LPR, since an 18% increase in hepatic mass is observed in animals in just 4 days after injection of an advanced EUK-LPR prototype. These results follow an extensive phase of preclinical optimization of the artificial gene whose expression is made possible by synthetic gene therapy. No signs of toxicity or poor tolerance have been observed in animals.
Philippe Jais, President & Scientific Director of Eukarÿs said: "We are delighted by these new results, which reinforce the considerable work undertaken over two years ago. EUK-LPR is designed to reduce the mortality of major hepatectomy, a major surgical procedure performed in more than 50,000 patients each year. We expect to start the regulatory phases at the end of 2020-early 2021 and the clinical phases by 2023. »
Publié le vendredi 6 décembre 2019 10:18
Eukarÿs is proud to announce winning the Galien MedStartUp Award 2019 in the category of Best Collaboration with the Pharmaceutical or Biotechnology Industry. This highly prestigious award, presented Thursday, October 24 in New York at the Alexandria Life Sciences Center, recognizes the best scientific innovations for human health. Eukarÿs partnership with the University of Alberta's Molecular Virology and Oncology Laboratory, led by Dr. Maya Shmulevitz, has been recognized. This collaboration has led to the development of the C3P3 system for viral bioproduction applications, particularly reoviruses used oncolytically. This award was presented by a committee chaired by Bernard Poussot (President of Roche Holding) and comprising leaders of the largest companies in the pharmaceutical industry (Sanofi, GSK, Pfizer, Johnson & Johnson, UCB) and venture capital (EvercorePartners).
Il n'y a pas encore d'organisations dans le réseau.
